227 related articles for article (PubMed ID: 22431533)
1. Plasma-diluted thrombin time to measure dabigatran concentrations during dabigatran etexilate therapy.
Avecilla ST; Ferrell C; Chandler WL; Reyes M
Am J Clin Pathol; 2012 Apr; 137(4):572-4. PubMed ID: 22431533
[TBL] [Abstract][Full Text] [Related]
2. Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.
Med Lett Drugs Ther; 2010 Nov; 52(1351):89-90. PubMed ID: 21068702
[TBL] [Abstract][Full Text] [Related]
3. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases.
Baetz BE; Spinler SA
Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996
[TBL] [Abstract][Full Text] [Related]
4. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
Bovio JA; Smith SM; Gums JG
Ann Pharmacother; 2011 May; 45(5):603-14. PubMed ID: 21540406
[TBL] [Abstract][Full Text] [Related]
5. Hemopericardium in a patient treated with dabigatran etexilate.
Barton CA; McMillian WD; Raza SS; Keller RE
Pharmacotherapy; 2012 May; 32(5):e103-7. PubMed ID: 22488474
[TBL] [Abstract][Full Text] [Related]
6. Bleeding with dabigatran (Pradaxa).
Med Lett Drugs Ther; 2011 Dec; 53(1379-1380):98. PubMed ID: 22173427
[TBL] [Abstract][Full Text] [Related]
7. Dabigatran etexilate, a new oral direct thrombin inhibitor, for stroke prevention in patients with atrial fibrillation.
Siddiqui FM; Qureshi AI
Expert Opin Pharmacother; 2010 Jun; 11(8):1403-11. PubMed ID: 20446854
[TBL] [Abstract][Full Text] [Related]
8. Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.
Huisman MV; Lip GY; Diener HC; Brueckmann M; van Ryn J; Clemens A
Thromb Haemost; 2012 May; 107(5):838-47. PubMed ID: 22318514
[TBL] [Abstract][Full Text] [Related]
9. Dabigatran for stroke prevention in atrial fibrillation: from RE-LY to daily clinical practice.
Heidbuchel H; Verhamme P
Acta Cardiol; 2010 Oct; 65(5):491-7. PubMed ID: 21125969
[TBL] [Abstract][Full Text] [Related]
10. Hospital-based clinical implications of the novel oral anticoagulant, dabigatran etexilate, in daily practice.
Wilcox R; Pendleton RC; Smock KJ; Rodgers GM
Hosp Pract (1995); 2011 Aug; 39(3):23-34. PubMed ID: 21881389
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran in clinical practice.
Nagarakanti R; Ellis CR
Clin Ther; 2012 Oct; 34(10):2051-60. PubMed ID: 23031622
[TBL] [Abstract][Full Text] [Related]
12. Focus on 2010 ESC Congress: new ESC guidelines and data on dabigatran.
Aalbers J
Cardiovasc J Afr; 2010; 21(5):300-1. PubMed ID: 20972525
[No Abstract] [Full Text] [Related]
13. Treatments for stroke prevention in atrial fibrillation: a network meta-analysis and indirect comparisons versus dabigatran etexilate.
Roskell NS; Lip GY; Noack H; Clemens A; Plumb JM
Thromb Haemost; 2010 Dec; 104(6):1106-15. PubMed ID: 20967400
[TBL] [Abstract][Full Text] [Related]
14. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
Ma TK; Yan BP; Lam YY
Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
[TBL] [Abstract][Full Text] [Related]
15. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
Paikin JS; Haroun MJ; Eikelboom JW
Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
[TBL] [Abstract][Full Text] [Related]
16. Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation.
Lip GY; Larsen TB; Skjøth F; Rasmussen LH
J Am Coll Cardiol; 2012 Aug; 60(8):738-46. PubMed ID: 22575324
[TBL] [Abstract][Full Text] [Related]
17. Dabigatran etexilate: A novel oral direct thrombin inhibitor.
Blommel ML; Blommel AL
Am J Health Syst Pharm; 2011 Aug; 68(16):1506-19. PubMed ID: 21817082
[TBL] [Abstract][Full Text] [Related]
18. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).
Van de Werf F; Brueckmann M; Connolly SJ; Friedman J; Granger CB; Härtter S; Harper R; Kappetein AP; Lehr T; Mack MJ; Noack H; Eikelboom JW
Am Heart J; 2012 Jun; 163(6):931-937.e1. PubMed ID: 22709744
[TBL] [Abstract][Full Text] [Related]
19. Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor.
Stangier J; Clemens A
Clin Appl Thromb Hemost; 2009; 15 Suppl 1():9S-16S. PubMed ID: 19696042
[TBL] [Abstract][Full Text] [Related]
20. Should dabigatran replace warfarin for stroke prevention in AF?
Drug Ther Bull; 2011 Oct; 49(10):114-7. PubMed ID: 21994438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
